ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för foretinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

29 träffar

Bibliografisk träff 2024-06-13

The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells.

Kucinska M, Pospieszna J, Tang J, Lisiak N, Toton E, Rubis B, Murias M.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2024.116892

Bibliografisk träff 2024-03-01

Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.

Wang P, Zhang Y, Xiang R, Yang J, Xu Y, Deng T, Zhou W, Wang C, Xiao X, Wang S.

Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/0008-5472.can-23-1534

Bibliografisk träff 2024-02-15

Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.

Nazari S, Mosaffa F, Poustforoosh A, Mortazavi M, Saso L, Firuzi O, Moosavi F.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2024.116866

Bibliografisk träff 2023-01-01

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling.

Ji X, Meng X, He Q, Xiang X, Shi Y, Zhu X.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms24010757

Bibliografisk träff 2022-10-20

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

PLOS ONE Editors.

PLoS One · published erratum; correction · DOI 10.1371/journal.pone.0276650

Bibliografisk träff 2022-10-10

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One · published erratum; correction · DOI 10.1371/journal.pone.0276211

Bibliografisk träff 2022-06-11

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.

Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.

J Hematol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13045-022-01299-z

Bibliografisk träff 2022-05-19

Foretinib mitigates cutaneous nerve fiber loss in experimental diabetic neuropathy.

Daeschler SC, Zhang J, Gordon T, Borschel GH, Feinberg K.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-022-12455-3

Bibliografisk träff 2021-12-23

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One · published erratum; correction · DOI 10.1371/journal.pone.0261994

Bibliografisk träff 2021-07-08

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma.

Fu Y, Peng Y, Zhao S, Mou J, Zeng L, Jiang X, Yang C, Huang C, Li Y, Lu Y, Wu M, Yang Y, Kong T, Lai Q, Wu Y, Yao Y, Wang Y, Gou L, Yang J.

Front Cell Dev Biol · research-article; journal article · DOI 10.3389/fcell.2021.689727

Bibliografisk träff 2021-05-03

Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.

Grojean M, Schwarz MA, Schwarz JR, Hassan S, von Holzen U, Zhang C, Schwarz RE, Awasthi N.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.16362

Bibliografisk träff 2021-04-15

Response surface methodology for optimization of micellar-enhanced spectrofluorimetric method for assay of foretinib in bulk powder and human urine.

Darwish HW, Bakheit AH, Al-Anazi ZS, Al-Shakliah NS, Al-Hossaini AM, Naguib IA, Darwish IA.

Spectrochim Acta A Mol Biomol Spectrosc · journal article · DOI 10.1016/j.saa.2021.119811

Bibliografisk träff 2021-03-10

Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.

Gortany NK, Panahi G, Ghafari H, Shekari M, Ghazi-Khansari M.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-021-04242-0

Bibliografisk träff 2020-05-21

LC-MS/MS assay for the quantification of foretinib in rat plasma and its application to preclinical pharmacokinetic study.

Guo N, Zhang A, Zhuang H, Zhang C.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.4862

Bibliografisk träff 2020-05-03

Development of innovative artificial neural networks for simultaneous determination of lapatinib and foretinib in human urine by micellar enhanced synchronous spectrofluorimetry.

Darwish HW, Bakheit AH, Al-Shakliah NS, Darwish IA.

Spectrochim Acta A Mol Biomol Spectrosc · validation study; journal article · DOI 10.1016/j.saa.2020.118438

Bibliografisk träff 2020-02-03

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling.

Sohn SH, Kim B, Sul HJ, Choi BY, Kim HS, Zang DY.

Onco Targets Ther · research-article; journal article · DOI 10.2147/ott.s226951

Bibliografisk träff 2020-01-31

UPLC-MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats.

Ezzeldin E, Iqbal M, Asiri YA, Ali AA, Ali AA, El Nahhas T.

Saudi Pharm J · research-article; journal article · DOI 10.1016/j.jsps.2020.01.013

Bibliografisk träff 2019-11-26

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.

Hassan MS, Williams F, Awasthi N, Schwarz MA, Schwarz RE, Li J, von Holzen U.

Sci Rep · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-019-54129-7

Bibliografisk träff 2019-08-02

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors.

Collie GW, Koh CM, O'Neill DJ, Stubbs CJ, Khurana P, Eddershaw A, Snijder A, Mauritzson F, Barlind L, Dale IL, Shaw J, Phillips C, Hennessy EJ, Cheung T, Narvaez AJ.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00276

Bibliografisk träff 2019-06-20

Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation.

Alanazi MM, Alkahtani HM, Almehizia AA, Attwa MW, Bakheit AH, Darwish HW.

RSC Adv · research-article; journal article · DOI 10.1039/c9ra03251g

Bibliografisk träff 2018-04-27

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer.

Kogata Y, Tanaka T, Ono YJ, Hayashi M, Terai Y, Ohmichi M.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.25232

Bibliografisk träff 2018-04-08

A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate.

Attwa MW, Kadi AA, Darwish HW, Amer SM, Alrabiah H.

Eur J Mass Spectrom (Chichester) · evaluation study; journal article · DOI 10.1177/1469066718768327

Bibliografisk träff 2018-04-06

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.

Dratkiewicz E, Pietraszek-Gremplewicz K, Simiczyjew A, Mazur AJ, Nowak D.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.24810

Bibliografisk träff 2016-11-07

Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.

Heinzlmeir S, Kudlinzki D, Sreeramulu S, Klaeger S, Gande SL, Linhard V, Wilhelm M, Qiao H, Helm D, Ruprecht B, Saxena K, Médard G, Schwalbe H, Kuster B.

ACS Chem Biol · research support, non-u.s. gov't; journal article · DOI 10.1021/acschembio.6b00709

Bibliografisk träff 2013-04-01

Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Logan TF.

Curr Oncol Rep · review; journal article · DOI 10.1007/s11912-013-0299-3

Bibliografisk träff 2013-03-14

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1371/journal.pone.0054014

Bibliografisk träff 2012-08-24

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1007/s10637-012-9861-3

Bibliografisk träff 2010-09-15

A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.

Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM.

Invest New Drugs · comparative study; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s10637-010-9536-x

Bibliografisk träff 2009-10-06

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res · journal article · DOI 10.1158/0008-5472.can-08-4889